Castle Biosciences Inc
(NAS:CSTL)
$
22.92
0.24 (1.06%)
Market Cap: 632.76 Mil
Enterprise Value: 418.60 Mil
PE Ratio: 0
PB Ratio: 1.57
GF Score: 80/100 - Q4 2023 Castle Biosciences Inc Earnings Call TranscriptFeb 28, 2024$24.39 (-2.79%)Earnings
- Q3 2023 Castle Biosciences Inc Earnings Call TranscriptNov 02, 2023$16.65 (+6.05%)Earnings
- Castle Biosciences Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Q2 2023 Castle Biosciences Inc Earnings Call TranscriptAug 02, 2023$16.79 (+0.42%)Earnings
- Q1 2023 Castle Biosciences Inc Earnings Call TranscriptMay 03, 2023$22.91 (+3.85%)Earnings
- Castle Biosciences Inc at Needham Healthcare Conference (Virtual) TranscriptApr 19, 2023
- Q4 2022 Castle Biosciences Inc Earnings Call TranscriptFeb 28, 2023$25.18 (+1.70%)Earnings
- Castle Biosciences Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Q3 2022 Castle Biosciences Inc Earnings Call TranscriptNov 02, 2022$24.77 (-4.07%)Earnings
- Castle Biosciences Inc To Host 2022 Investor Day TranscriptSep 20, 2022
- Castle Biosciences Inc at Robert W Baird Global Healthcare Conference TranscriptSep 13, 2022
- Castle Biosciences Inc at Canaccord Genuity Growth Conference TranscriptAug 10, 2022
- Q2 2022 Castle Biosciences Inc Earnings Call TranscriptAug 08, 2022$28.48 (-6.81%)Earnings
- Castle Biosciences Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Castle Biosciences Inc Earnings Call TranscriptMay 09, 2022$19.17 (-9.36%)Earnings
- Castle Biosciences Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Castle Biosciences Inc To Acquire AltheaDx Inc Call TranscriptApr 04, 2022
- Castle Biosciences Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) TranscriptMar 22, 2022
- Q4 2021 Castle Biosciences Inc Earnings Call TranscriptFeb 28, 2022$43.29 (-3.13%)Earnings
- Castle Biosciences Inc at Needham Growth Conference (Virtual) TranscriptJan 10, 2022
- Q3 2021 Castle Biosciences Inc Earnings Call TranscriptNov 08, 2021$61.51 (+3.29%)Earnings
- Castle Biosciences Inc To Acquire Cernostics Inc Call TranscriptOct 19, 2021
- Q2 2021 Castle Biosciences Inc Earnings Call TranscriptAug 09, 2021$71.85 (+0.04%)Earnings
- Q1 2021 Castle Biosciences Inc Earnings Call TranscriptMay 10, 2021$54.78 (-9.18%)Earnings
- Castle Biosciences Inc to Acquire Myriad myPath® Laboratory TranscriptApr 27, 2021
- Q4 2020 Castle Biosciences Inc Earnings Call TranscriptMar 08, 2021$66.08 (-4.20%)Earnings
- Q3 2020 Castle Biosciences Inc Earnings Call TranscriptNov 09, 2020$47.78 (-7.58%)Earnings
- Castle Biosciences, Inc. - Special Call TranscriptOct 28, 2020
- Castle Biosciences, Inc. - Special Call TranscriptSep 02, 2020
- Q2 2020 Castle Biosciences Inc Earnings Call TranscriptAug 10, 2020$41.54 (-0.62%)Earnings
- Q1 2020 Castle Biosciences Inc Earnings Call TranscriptMay 11, 2020$32.5 (+3.17%)Earnings
- Castle Biosciences Inc at Needham Healthcare Conference TranscriptApr 15, 2020
- Q4 2019 Castle Biosciences Inc Earnings Call TranscriptMar 10, 2020$29.36 (-0.20%)Earnings
- Q3 2019 Castle Biosciences Inc Earnings Call TranscriptNov 11, 2019Earnings
Castle Biosciences Inc at Canaccord Genuity Growth Conference Transcript
Aug 10, 2022 / 05:00PM GMT
Release Date Price:
$34.32
(+12.01%)
Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst
Hi, everyone. Welcome to the Canaccord Genuity 42nd Annual Global Growth Conference. I'm Kyle Mikson. I cover Life Science Tools and Diagnostics at Canaccord, and I'm pleased to present to you the management team from Castle Biosciences here with us today. We have Derek Maetzold, CEO; and then Frank Stokes, CFO. Thanks, Derek, Frank, for joining us today.
Derek J. Maetzold
Castle Biosciences, Inc. - Founder, CEO, President & Director
Thank you, Kyle.
Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst
And just as background, Castle provides a leading class of dermatologic cancer tests as well as now GI cancer tests, prognostic tests as well as mental health tests, too. So we're going to cover all that today. Looking forward to it.
Questions & Answers
Kyle Alexander Mikson
Canaccord Genuity Corp., Research Division - Analyst
So maybe just on the second
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)